Mendelian randomization analysis of 71 serum proteins altered by the DASH diet in prior randomized feeding trials pinpointed four proteins — ANGPTL3, INHBC, PCOLCE, and PLXNB2 — with causal evidence of beneficial effects on cardiovascular and metabolic risk factors. Crucially, missense variants in INHBC are genetically associated with lower coronary artery disease (CAD) risk, while PLXNB2 variants correlate with reduced type 2 diabetes (T2D) risk — both directionally concordant with DASH-induced protein changes, strengthening the causal inference.
This work addresses a persistent gap: while DASH's blood pressure and cholesterol benefits are well-established, the molecular machinery driving those effects — and whether they translate to hard endpoints like CAD and T2D — has remained opaque. By chaining randomized protein-level data with genetic instruments, the authors sidestep confounding that plagues observational diet studies. ANGPTL3, already a validated lipid-modulating target in pharmacology, appearing here suggests DASH may partially mimic emerging therapeutic strategies. INHBC and PLXNB2 are less characterized clinically, making them genuinely novel mechanistic candidates worth prioritizing in follow-up drug-target trials.
Limitations are real: Mendelian randomization assumes genetic variants proxy the protein faithfully and requires replication in diverse ancestries. Effect sizes on actual disease incidence remain unquantified. This is a preprint posted on medRxiv and has not yet been peer-reviewed — findings should be treated as hypothesis-generating. If confirmed, this represents a meaningful advance: translating dietary pattern science into actionable protein targets for both precision nutrition and drug discovery.